封面
市场调查报告书
商品编码
1611215

北美单位剂量製造市场规模、份额和趋势分析报告:2025-2030 年按来源、产品、最终用途、国家和细分市场进行的预测

North America Unit Dose Manufacturing Market Size, Share & Trends Analysis Report By Sourcing (In-house, Outsourcing), By Product (Liquid Unit Dose, Solid Unit Dose), By End Use, By Country, And Segment Forecasts, 2025 - 2030

出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格

北美单位剂量製造市场的成长与趋势

北美单位剂量製造市场规模预计到2030年将达到562.2亿美元,2025年至2030年复合年增长率为11.23%。製药业的快速成长和单位剂量需求的不断增长是推动市场的因素。

单剂量包装无疑已成为近年来最受欢迎的趋势之一。最明显的好处是易于使用和改进的药物管理,因为它可以逐个单位进行复合,确保使用者不会超过其复合剂量。条状包装的特色是干湿两用,可用于包装多种物品。

量杯、茶匙、汤匙以及用于口服液和眼药水的多剂量容器已经随处可见。今天的患者想要便利。医生也认识到单位剂量在製定处方时的重要性。受管制药物的口服溶液可以配製而不必担心滥用,因为单位剂量可以解决这个问题。它还允许药剂师以安全的方式储存口服液体药物,这是另一个重要的好处。这项创新有可能将几乎所有单剂量口服固态和多剂量口服溶液转变为单剂量口服溶液。

然而,由于COVID-19大流行的影响,2020年单位剂量製造市场与前一年同期比较去年小幅成长11.0%。 2020年终,市场开始復苏。与 COVID-19 相关的疾病正在使用单位剂量进行治疗。在医疗保健领域,正在更新和实施各种新的标准作业程序,以保护病患和医护人员。因此,消除病毒透过空气传播和直接接触传播极为重要。当使用单位剂量药物时,与处理和注射同一瓶药物相关的一些风险会降低。

北美单位剂量製造市场报告亮点

  • 2024年,外包产业销售额占比最大,达60.13%,领先市场。单位剂量,加上对药剂师工作模式和时间表的更大控制,导致药物信用的最小化。
  • 固态单位剂量细分市场在 2024 年以 49.71% 的最大收益占有率引领市场。 2018年,口服固态製剂药物占FDA核准的所有新药的53%。
  • 独立药局细分市场在 2024 年以 37.83% 的最大收益占有率引领市场。
  • 2024 年,医院业务占第二大收益占有率。单位剂量包装可确保准确剂量,减少用药错误的可能性,并支持医院内的用药安全通讯协定。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章:北美单位剂量製造市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 助剂市场前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 技术景观
  • 定价模式分析
  • 市场分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影响分析

第 4 章 北美单位剂量製造市场:依来源估计与趋势分析

  • 细分仪表板
  • 北美单位剂量製造市场:采购变化分析
  • 按来源划分,2018-2030
  • 公司内部
  • 外包

第五章北美单位剂量製造市场:依产品估价及趋势分析

  • 细分仪表板
  • 北美单位剂量製造市场:产品变化分析
  • 按产品划分,2018-2030
  • 液体单位剂量
  • 固态单位剂量
  • 其他的

第六章北美单位剂量製造市场:最终用途的估计和趋势分析

  • 细分仪表板
  • 北美单位剂量製造市场:最终用途变化分析
  • 按最终用途划分,2018-2030
  • 独立药房
  • 长期照护设施
  • 医院
  • 其他的

第七章北美单位剂量製造市场:按国家、估计和趋势分析、按来源、按产品、按最终用途

  • 国家仪表板
  • 国家差异分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

第八章 竞争格局

  • 公司分类
    • 市场领导者
    • 参与企业
  • 2024 年企业市场分析(企业热图分析)
  • 公司简介
    • Catalent Inc.
    • Unither Pharmaceuticals
    • Thermo Fisher Scientific
    • Corden Pharma
    • Mikart
    • Tape Mark
    • Renaissance Lakewood LLC
    • Medical Packaging Inc
    • American Health Packaging
    • PCI Pharma Services
    • Amcor PLC
    • Bristol-Myers Squibb
    • AbbVie Inc.
    • Merck &Co. Inc.
    • Pfizer Inc.
Product Code: GVR-4-68038-396-6

North America Unit Dose Manufacturing Market Growth & Trends:

The North America unit dose manufacturing market size is expected to reach USD 56.22 billion in 2030 and is projected to grow at a CAGR of 11.23% from 2025 to 2030. The rapidly growing pharmaceutical industry and rising demand for unit doses are factors driving the market.

Single-dose packaging has certainly become one of the most popular recent trends. The most obvious benefit is its ease of use and improved medication management, as they can be prescribed by the unit, ensuring that the person taking it does not exceed the prescribed dose. Stick packs are unique in the way that they can be used to package a variety of items, both dry and wet.

Measuring cups, teaspoons, tablespoons, and multi-dose containers for oral liquids and eye drops have been already seen. The current patient is seeking convenience. Doctors are also appreciating the importance of unit dose in prescription writing since it allows them to prescribe controlled substance oral liquid without concern of abuse as unit doses address the issue. It also enables pharmacists to store oral liquids in a secure manner, which is a significant additional benefit. Nearly every single unit dose oral solid or multiple-dose oral liquid could be transformed to a unit dose oral liquid due to this innovation.

However, owing to the COVID-19 pandemic's repercussions, the unit dose manufacturing market increased at a modest 11.0% year over year in 2020. By the end of 2020, the market started to recover. COVID-19-related illnesses are being treated using unit dosages. Hospitals have updated and implemented various new standard operating procedures to protect both patients and healthcare workers. As a consequence, it's crucial to consider out viral transmission by airborne transmission or direct contact. When unit dose medicines are used, some of the risks involved with handling and pouring doses from the same bottle are reduced.

North America Unit Dose Manufacturing Market Report Highlights:

  • The outsourcing segment led the market with the largest revenue share of 60.13% in 2024. Unit doses lead to the minimization of credits for drugs coupled with greater control by a pharmacist over work patterns and schedules.
  • The solid unit dose segment led the market with the largest revenue share of 49.71% in 2024. In 2018, oral solid dosage medicines accounted for 53% of all new pharmaceuticals approved by the FDA.
  • The independent pharmacies segment led the market with the largest revenue share of 37.83% in 2024.
  • The hospitals segment accounted for the second-largest revenue share in 2024. Unit dose packaging ensures precise dosing, reduces the possibility of medication errors, and supports medication safety protocols within hospital settings.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. North America Unit Dose Manufacturing Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increased Adoption of Unit Doses
      • 3.2.1.2. Benefits of Manufacturing Unit Doses Over Repackaging
      • 3.2.1.3. Growing Outsourcing Activities
      • 3.2.1.4. Technological Advancements in Unit Dose Manufacturing
      • 3.2.1.5. Increasing Prevalence of Chronic Diseases and Demand for Personalized Medicine
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Challenges Associated with the Adoption of Manufactured Unit Doses
      • 3.2.2.2. Compliance Issues with Outsourcing
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Market Analysis Tools
    • 3.5.1. Porter's Five Forces Analysis
    • 3.5.2. PESTEL analysis
    • 3.5.3. COVID-19 Impact Analysis

Chapter 4. North America Unit Dose Manufacturing Market: Sourcing Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. North America Unit Dose Manufacturing Market: Sourcing Movement Analysis
  • 4.3. North America Unit Dose Manufacturing Market Estimates & Forecasts, by Sourcing, 2018 - 2030 (USD Million)
  • 4.4. In-House
    • 4.4.1. In-House Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Outsourcing
    • 4.5.1. Outsourcing Market Estimates & Forecasts, 2018 - 2030 (USD Million)

Chapter 5. North America Unit Dose Manufacturing Market: Product Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. North America Unit Dose Manufacturing Market: Product Movement Analysis
  • 5.3. North America Unit Dose Manufacturing Market Estimates & Forecasts, by Product, 2018 - 2030 (USD Million)
  • 5.4. Liquid Unit Dose
    • 5.4.1. Liquid Unit Dose Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Solid Unit Dose
    • 5.5.1. Solid Unit Dose Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market Estimates & Forecasts, 2018 - 2030 (USD Million)

Chapter 6. North America Unit Dose Manufacturing Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. North America Unit Dose Manufacturing Market: End Use Movement Analysis
  • 6.3. North America Unit Dose Manufacturing Market Estimates & Forecasts, by End Use, 2018 - 2030 (USD Million)
  • 6.4. Independent Pharmacies
    • 6.4.1. Independent Pharmacies Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Long Term Care Facility
    • 6.5.1. Long Term Care Facility Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Hospitals
    • 6.6.1. Hospitals Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Others Market Estimates & Forecasts, 2018 - 2030 (USD Million)

Chapter 7. North America Unit Dose Manufacturing Market: Country Estimates & Trend Analysis, by Sourcing, by Product, By End Use

  • 7.1. Country Dashboard
  • 7.2. Country Movement Analysis
  • 7.3. North America
    • 7.3.1. North America Unit Dose Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. U.S. Unit Dose Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Canada Unit Dose Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Mexico Unit Dose Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
    • 8.1.1. Market Leaders
    • 8.1.2. Emerging Players
  • 8.2. Company Market Position Analysis, 2024 (Company Heat Map Analysis)
  • 8.3. Company Profiles
    • 8.3.1. Catalent Inc.
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Service Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Unither Pharmaceuticals
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Service Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Thermo Fisher Scientific
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Service Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Corden Pharma
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Service Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Mikart
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Service Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Tape Mark
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Service Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Renaissance Lakewood LLC
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Service Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Medical Packaging Inc
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Service Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. American Health Packaging
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Service Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. PCI Pharma Services
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Service Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. Amcor PLC
      • 8.3.11.1. Company Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Service Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. Bristol-Myers Squibb
      • 8.3.12.1. Company Overview
      • 8.3.12.2. Financial Performance
      • 8.3.12.3. Service Benchmarking
      • 8.3.12.4. Strategic Initiatives
    • 8.3.13. AbbVie Inc.
      • 8.3.13.1. Company Overview
      • 8.3.13.2. Financial Performance
      • 8.3.13.3. Service Benchmarking
      • 8.3.13.4. Strategic Initiatives
    • 8.3.14. Merck & Co. Inc.
      • 8.3.14.1. Company Overview
      • 8.3.14.2. Financial Performance
      • 8.3.14.3. Service Benchmarking
      • 8.3.14.4. Strategic Initiatives
    • 8.3.15. Pfizer Inc.
      • 8.3.15.1. Company Overview
      • 8.3.15.2. Financial Performance
      • 8.3.15.3. Service Benchmarking
      • 8.3.15.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 North America Unit Dose Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 4 North America Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
  • Table 5 North America Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 6 North America Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 7 U.S. Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
  • Table 8 U.S. Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 9 U.S. Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 10 Canada Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
  • Table 11 Canada Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 12 Canada Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Unit Dose Manufacturing Market, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 Porter's Five Forces Analysis
  • Fig. 10 PESTEL Analysis by SWOT Analysis
  • Fig. 11 Regional Marketplace: Key Takeaways
  • Fig. 12 North America Unit Dose Manufacturing Market, for In-house, 2018 - 2030 (USD Million)
  • Fig. 13 North America Unit Dose Manufacturing Market, for Outsourcing, 2018 - 2030 (USD Million)
  • Fig. 14 North America Unit Dose Manufacturing Market, for Liquid Unit Dose, 2018 - 2030 (USD Million)
  • Fig. 15 North America Unit Dose Manufacturing Market, for Solid Unit Dose, 2018 - 2030 (USD Million)
  • Fig. 16 North America Unit Dose Manufacturing Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 17 North America Unit Dose Manufacturing Market, for Independent Pharmacies, 2018 - 2030 (USD Million)
  • Fig. 18 North America Unit Dose Manufacturing Market, for Long Term Care Facility, 2018 - 2030 (USD Million)
  • Fig. 19 North America Unit Dose Manufacturing Market, for Hospitals, 2018 - 2030 (USD Million)
  • Fig. 20 North America Unit Dose Manufacturing Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 21 Country Outlook, 2024 & 2030
  • Fig. 22 U.S. Unit Dose Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Canada Unit Dose Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Mexico Unit Dose Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)